PPIG and graft versus host disease: Overall, the developed popPK models resulted in an adequate description of Ruxolitinib pharmacokinetics in GvHD patients, but the observed covariate effect should be interpreted with care due to the low number of patients without CYP-inhibiting comedication and the explorative nature of the analysis (no p value correction for multiple testing).